Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Orthocell.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Fisher & Paykel Healthcare shares tumble after Trump tariff king-hit
Health & Biotech
Orthocell soars 14% after crushing early sales growth for Remplir
News
Closing Bell: Iron ore miners hammered, but Trump’s Canada tariffs boost uranium stocks
Health & Biotech
Health Check: We’ll see you in court and you bladder believe it, says Pacific Edge after unfavourable US ruling
News
ASX Lunch Wrap: ASX lifts; Star tumbles; Trump (and his volatile meme coin) firmly in focus
News
Closing Bell: ASX surges after inflation shock; banks and goldies lead the charge
Health & Biotech
Health Check: Which stock just dumped 19% on earnings downgrade?
Health & Biotech
Orthocell achieves third consecutive quarter of record revenue
Health & Biotech
ASX December health sector winners… and a 91pc drop for a trial-flopped stock
News
ASX December Winners: Santa didn’t rally but at least these 50 stocks went okay
Health & Biotech
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health & Biotech
Orthocell files FDA application to sell nerve-repair product in the US
Health & Biotech
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
Health & Biotech
First sales in Singapore for Orthocell’s nerve-repair product Remplir
News
Closing Bell: ASX slides from record high; expert says December pullback may encourage buying
Stockhead TV
Break it Down: Orthocell’s pivotal path into US healthcare market
Health & Biotech